DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

628 therapy for advanced Parkinson’s disease. Ann Neurol, 1990,
27:18–23.
Olanow CW, Hauser RA, Jankovic J, et al. A randomized,
double-blind, placebo-controlled, delayed start study to assess
rasagiline as a disease modifying therapy in Parkinson’s disease
(the ADAGIO study): Rationale, design, and baseline
characteristics. Mov Disord, 2008, 23:2194–2201.
Parent A, Cicchetti F. The current model of basal ganglia organization
under scrutiny. Mov Disord, 1998, 13:199–202.
Parkinson Study Group. Effects of tocopherol and deprenyl
on the progression of disability in early Parkinson’s disease.
N Engl J Med, 1993, 328:176–183.
Parkinson Study Group. Entacapone improves motor fluctuations
in levodopa-treated Parkinson’s disease patients. Ann
Neurol, 1997, 42:747–755. Published erratum appears in Ann
Neurol, 1998, 44:292.
Parkinson Study Group. Pramipexole vs. levodopa as initial
treatment for Parkinson’s disease: A randomized, controlled
trial. JAMA, 2000, 284:1931–1938.
Parkinson Study Group. Dopamine transporter imaging to asses
the effects of pramipexole vs levodopa on Parkinson disease
progression. JAMA, 2002, 287:1653–1661.
Perry EK. The cholinergic hypothesis—ten years on. Br Med
Bull, 1986, 42:63–69.
Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and
donepezil for the treatment of mild cognitive impairment. N Engl
J Med, 2005, 352:2379–2388.
Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the
vast majority of AD risk and AD pathology. Neurobiol Aging,
2004, 25:641–650.
Raina P, Santaguida P, Ismaila A, et al. Effectiveness of
cholinesterase inhibitors and memantine for treating dementia:
Evidence review for a clinical practice guideline. Ann Intern
Med, 2008, 148:379–397.
Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase
inhibitors in mild cognitive impairment: A systematic review of
randomised trials. PLoS Med, 2007, 4:e338.
Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study
of the incidence of dyskinesia in patients with early
Parkinson’s disease who were treated with ropinirole or
levodopa. 056 Study Group. N Engl J Med, 2000, 342:
1484–1491.
Roberson ED, Mucke L. 100 years and counting: Prospects for
defeating Alzheimer’s disease. Science, 2006, 314:781–784.
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn
superoxide dismutase gene are associated with familial amyotrophic
lateral sclerosis. Nature, 1993, 362:59–62. Published
erratum appears in Nature, 1993, 364:362.
Rothstein JD. Current hypotheses for the underlying biology of
amyotrophic lateral sclerosis. Ann Neurol, 2009, 65(Suppl 1):
S3–S9.
Rothstein JD, Marin LJ, Kuncl RW. Decreased glutamate transport
by the brain and spinal cord in amyotrophic lateral sclerosis.
N Engl J Med, 1992, 326:1464–1468.
SECTION II
NEUROPHARMACOLOGY
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical
antipsychotic drug treatment for dementia: Meta-analysis
of randomized placebo-controlled trials. JAMA, 2005,
294:1934–1943.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of
atypical antipsychotic drugs in patients with Alzheimer’s disease.
N Engl J Med, 2006, 355:1525–1538.
Selkoe DJ, Podlisny MB. Deciphering the genetic basis of
Alzheimer’s disease. Annu Rev Genomics Hum Genet, 2002,
3:67–99.
Sheean G. Neurophysiology of spasticity. In, Upper Motor Neurone
Syndrome and Spasticity: Clinical Management and Neuro -
physiology, 2nd ed. (Barnes MP, Johnson GR, eds.) Cambridge
University Press, Cambridge, England, 2008, pp. 9–63.
Shoulson I. Huntington’s disease. In, Diseases of the Nervous
System: Clinical Neurobiology. (Asbury AK, McKhann GM,
McDonald WI, eds.) Saunders, Philadelphia, 1992, pp.
1159–1168.
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10
in early Parkinson disease: Evidence of slowing of the functional
decline. Arch Neurol, 2002, 59:1541–1550.
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of
neuropsychiatric symptoms of dementia: A review of the evidence.
JAMA, 2005, 293:596–608.
Strong MJ, Grace GM, Freedman M, et al. Consensus criteria
for the diagnosis of frontotemporal cognitive and behavioural
syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral
Scler, 2009, DOI: 10.1080/17482960802654364.
Tandan R, Bradley WG. Amyotrophic lateral sclerosis: 2.
Etiopathogenesis. Ann Neurol, 1985, 18:419–431.
Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin,
1992, 10:317–329.
Tanzi R, Bertram L. Twenty years of the Alzheimer’s disease
amyloid hypothesis: A genetic perspective. Cell, 2005, 120:
545–555.
Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of
cholinesterase inhibitors in the treatment of neuropsychiatric
symptoms and functional impairment in Alzheimer disease: A
meta-analysis. JAMA, 2003, 289:210–216.
Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological
classification of Huntington’s disease. J Neuropathol Exp
Neurol, 1985, 44:559–577.
Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of
Parkinson’s disease with ropinirole versus levodopa: The
REAL-PET study. Ann Neurol, 2003, 54:93–101.
Wichmann T, DeLong MR. Pathophysiology of parkinsonian
motor abnormalities. Adv Neurol, 1993, 60:53–61.
Yacoubian TA, Standaert DG. Targets for neuroprotection in
Parkinson’s disease. Biochim Biophys Acta, 2008, DOI:
10.1016/j.bbadis.2008.09.009.
Zarate CA, Manji HK. Riluzole in psychiatry: A systematic
review of the literature. Expert Opin Drug Metab Toxicol,
2008, 4:1223–1234.